AU2003203346A1 - Non-steroidal anti inflammatory drug and glucosamine combination - Google Patents
Non-steroidal anti inflammatory drug and glucosamine combination Download PDFInfo
- Publication number
- AU2003203346A1 AU2003203346A1 AU2003203346A AU2003203346A AU2003203346A1 AU 2003203346 A1 AU2003203346 A1 AU 2003203346A1 AU 2003203346 A AU2003203346 A AU 2003203346A AU 2003203346 A AU2003203346 A AU 2003203346A AU 2003203346 A1 AU2003203346 A1 AU 2003203346A1
- Authority
- AU
- Australia
- Prior art keywords
- analgesic
- glucosamine
- wherin
- dosage form
- analgesic compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Description The invention relates to analgesic compositions which comprise of a glucosamine type material in combination with an analgesic compound.Depending on the choice of analgesic compound and the weight ratio of glucosamine to analgesic compound, the analgesic efficacy of the composition may be either additive, super-additive or synergystic. The most commonly used analgesics are Non Steroidal anti-inflammatory drugs(NSAIDs)such as Ibuprofen and also opiate like analgesics such as morphine. Both exhibit adverse effects.Opiates can cause constipation and NSAIDs can cause stomach ulceration. NSAIDs have been combined with other analgesics including opiates in order to achive synergystic effects. An example is US Pat No. 4571400 which discloses the combination of dihydrocodeine and ibuprofen (Opiate +NSAID) provide super additive analgesia when combined in certain ratios. It is known however that it is undesirable to consume opiates long term and that specifically certain combinations may provide sub-additive levels of analgesia. Glucosamine is an essential intermediate in the biosynthetic pathway of proteoglycans,which are the primary building block of connective tissue and cartilage. Glucosamine compounds exhibit WEAK anti-inflammatory activity but NO analgesic activity. Prior scientific literature emphasises the need to replace NSAIDs with glucosamine(because of the adverse effects associated with NSAIDs)and many existing glucosamine containing products emphasise the fact that they are analgesic free. Further, certain combinations of glucosamine and analgesics, provide SUB-additive analgesia. The object of the present invention is to combine Glucosamine with a therapeutic amount of analgesic compound to provide an analgesic composition which provides analgesia at least equal to and in many cases substantially greater than that of the analgesic compound alone. The combination of glucosamine with an analgesic compound at an appropriate ratio will synergystically enhance the analgesic effect of the analgesic compound, such as an NSAID, so that less analgesic compound is needed to produce effective analgesia and potential side effects are accordingly reduced. In addition the combination of glucosamine with an analgesic is also expected to retain the beneficial effects on restoration and maintanence of cartilage. In compositions of the present invention, the glucosamine material may be one or more of the following: The alpha or beta form of glucosamine or mixture therof, N-acetylglucosamine or various pharmaceutically acceptable salts of any of them, in particular glucosamine sulphate or glucosamine HCL. It doesnt include glucosamine salts which have an analgesic acitivity of their own. In the present invention we focus on any drug classed as a Non steroidal anti inflammatory drug (NSAID) but especially focus on Ibuprofen, ketoprofen and any of the propionic acid derivatives. Other analgesics suitable for use in the present invention (other than NSAIDs)are opiates. THus the compositions of this present invention include those where the analgesic compound is an opiate, NSAID or non opoid analgesic including physiologically active and pharmaceutically acceptable salts and isomers therof. One or more of the analgesics may be employed for example a single NSAID or a combination of NSAIDs. The NSAID or other analgesic and the glucosamine are generally present in a weight ratio of glucosamine:analgesic(1:2).But this ratio may be varied widely.
Claims (13)
1. A dosage form for the treatment of pain comprising a glucosamine material and a therapeutic amount of an analgesic compound, wherin the weight ratio of glucosamine material to analgesic compound is such that the analgesic efficacy of the dosage form is equal to or greater than the anagesic efficacy of the analgesic compound alone at the dosage level for the analgesic compound.
2.The dosage form of claim 1, wherin the weight ratio of the glucosamine materail to the analgesic compound is such that the analgesic efficacy of the dosage form is enhanced over the analgesic efficacy of the analgesic compound alone.
3. The dosage form of claim 2 wherin the analgesic compound is a NSAID.
4. THe dosage form of claim 3 wherin the analgesic compound is a propionic acid analgesic. THe dosage form of claim 4 wherin the analgesic compound is Ibuprofen.
6. The dosage form of claim 4 wherin the analgesic compound is Ketoprofen.
7. The dosage forms of claims 1 or 2 wherin the glucosamine material is glucosamine or a pharmaceutically acceptable salt therof
8. The dosage form of claim 7 wherin the weight ratio of glucosamine to analgesic compound is atleast 1:2
9. The dosage form in claim 8 wherin the weight ratio of glucosamine to analgesic compound is in the range of 1:2 to 100:1 THe doage form of claim 4 wherin the weight ratio of glucosamine to analgesic compound is in the range 1:2 to 10:1
11. The dosage form of claim 10 in which the analgesic compound is selected from Ibuprofen and Ketoprofen
12. THe dosage form of claims 1 or 2 further comprising a therapeutic amount of an antiarthritic, antihistamine, muscle relaxent, sleep aid, decongestant, bronchodilator or mixture therof.
13. The dosage forms of claims lor 2 comprising a pharmaceutical or vetinary product.
14. A method to alleviate pain in a human patient, which comprises administering a therapeutically effective amount of a dosage form of claims 1 or 2. THe method of claim 14, wherin the dosage form is in the form of a dosage unit containing from 0.1 to about 850mg/kg of analgesic and glucosamine material. 4
16. The method of claim 14, comprising administering to a patient an analgesic compound in a mixture with glucosamine, wherin the analgesic compound is Ibuprofen, Ketoprofen or a combination therof or a pharmaceutically acceptable salt of either of them, the glucosamine comprises alpha or beta glucosamine or N-acetylglucosamine or glucosamine sulphate or glucosamine HCL, the ratio of glucosamine to analgesic compound is in the range of 1:2 to 10:1, and wherin, at said ratio the analgesic efficacy of said analgesic composition is enhanced over the analgesic efficacy of the analgesic compound alone.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003203346A AU2003203346A1 (en) | 2003-03-30 | 2003-03-30 | Non-steroidal anti inflammatory drug and glucosamine combination |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003203346A AU2003203346A1 (en) | 2003-03-30 | 2003-03-30 | Non-steroidal anti inflammatory drug and glucosamine combination |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2003203346A1 true AU2003203346A1 (en) | 2004-10-21 |
Family
ID=34318245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003203346A Abandoned AU2003203346A1 (en) | 2003-03-30 | 2003-03-30 | Non-steroidal anti inflammatory drug and glucosamine combination |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2003203346A1 (en) |
-
2003
- 2003-03-30 AU AU2003203346A patent/AU2003203346A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4681897A (en) | Pharmaceutical products providing enhanced analgesia | |
AU589554B2 (en) | Nsaids in cough/cold mixtures | |
US6689399B1 (en) | Transdermal delivery of an anti-inflammatory composition | |
WO1988008302A1 (en) | Cough/cold mixtures comprising non-sedating antihistamine drugs | |
US6608041B2 (en) | Analgesics combined with naturally-occurring chondroprotective agents | |
US20190374491A1 (en) | Topical preparation for pain relief | |
US6900189B2 (en) | Analgesic and glucosamine compositions | |
KR20100017268A (en) | Tapentadol for treating pain from arthritis | |
US20120064152A1 (en) | Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same | |
CA2476939A1 (en) | Pharmaceutical combinations of cox-2 inhibitors and opiates | |
CN100376245C (en) | Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent | |
ES2694506T3 (en) | Administration of intravenous ibuprofen | |
WO2004050025A3 (en) | Combination of ibuprofen and oxycodone for acute pain relief | |
JP2005519936A5 (en) | ||
JPH09502202A (en) | Composition containing amino acid salt of propionic acid non-steroidal anti-inflammatory drug and caffeine | |
JP2008195705A (en) | Loxoprofen-containing oral composition | |
US8148425B2 (en) | Pharmaceutical composition containing phloroglucinol and paracetamol | |
US4730007A (en) | Novel analgesic compositions | |
AU2003203346A1 (en) | Non-steroidal anti inflammatory drug and glucosamine combination | |
GB2286528A (en) | Dietary supplement | |
EP0027991A1 (en) | Use of combination of compounds for alleviating pain | |
EP2106258A2 (en) | Non-steroid antiphlogistics against coughing | |
Hersh et al. | Narcotic receptor blockade and its effect on the analgesic response to placebo and ibuprofen after oral surgery | |
US20130109754A1 (en) | Combination of an nsaid and an amino acid | |
AU738274B2 (en) | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |